UBS Group AG Decreases Holdings in Celcuity, Inc. $CELC

UBS Group AG cut its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 90.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 81,571 shares of the company’s stock after selling 772,912 shares during the quarter. UBS Group AG’s holdings in Celcuity were worth $8,136,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Soleus Capital Management L.P. raised its stake in shares of Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Celcuity by 10.7% during the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after acquiring an additional 220,386 shares in the last quarter. Apis Capital Advisors LLC purchased a new position in shares of Celcuity during the third quarter worth approximately $38,334,000. Ameriprise Financial Inc. raised its stake in shares of Celcuity by 27.6% during the second quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock worth $10,263,000 after acquiring an additional 166,324 shares in the last quarter. Finally, Deerfield Management Company L.P. purchased a new position in shares of Celcuity during the third quarter worth approximately $36,236,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Craig Hallum reissued a “buy” rating and set a $189.00 price target on shares of Celcuity in a research note on Monday, May 4th. Citigroup reissued an “outperform” rating on shares of Celcuity in a research note on Monday, May 4th. Guggenheim lifted their price target on shares of Celcuity from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Wells Fargo & Company raised their target price on shares of Celcuity from $150.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and issued a $157.00 target price on shares of Celcuity in a report on Friday. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Celcuity presently has a consensus rating of “Moderate Buy” and an average target price of $140.20.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity announced amendments to its Phase 3 VIKTORIA-2 trial for gedatolisib, expanding the study to include endocrine-sensitive patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The broader trial population could increase the drug’s commercial opportunity if results remain positive. Article Title
• Positive Sentiment: Needham & Company reiterated its Buy rating on Celcuity and raised its price target to $157, signaling continued analyst confidence in the company’s pipeline and upside potential. Article Title
• Positive Sentiment: Celcuity reported first-quarter 2026 earnings of ($0.97) per share, beating consensus estimates of ($1.07). While the company is still unprofitable, the smaller-than-expected loss likely supported investor sentiment. Article Title
• Neutral Sentiment: Celcuity also provided its first-quarter financial results and a corporate update, but the main market focus appears to be on the trial expansion and analyst upgrades rather than the broader financial details. Article Title
• Neutral Sentiment: An earnings call transcript was published for the quarter, which may help investors assess management’s commentary on trial progress, cash needs, and commercialization plans. Article Title

Insider Activity at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,000 shares of company stock worth $5,111,950 in the last 90 days. Company insiders own 13.33% of the company’s stock.

Celcuity Price Performance

Shares of Celcuity stock opened at $137.68 on Monday. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. Celcuity, Inc. has a 52-week low of $10.26 and a 52-week high of $151.02. The stock has a market capitalization of $6.71 billion, a price-to-earnings ratio of -35.30 and a beta of 0.09. The company’s 50 day moving average price is $118.86 and its 200-day moving average price is $106.94.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. Equities research analysts forecast that Celcuity, Inc. will post -3.87 EPS for the current year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.